Jan 21 (Reuters) - BELLUS Health Inc BLU.TO :
* Auven Therapeutics and Bellus Health announce completion of pivotal Phase 3
confirmatory trial of KIACTA for the treatment of orphan disease AA
amyloidosis
* Top-line results are expected to be announced in Q2 2016 after all remaining
patients have completed final study visits
* Source text for Eikon Further company coverage BLU.TO